Skip to main content

Table 3 Logistic regression analysis of serum biomarkers and fatty lesion development visualized by magnetic resonance imaging

From: Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study

 

Fatty lesion development, odds ratio (95% confidence interval); p value

Serum biomarker, time

Week 14 (n = 125)

Week 104 (n = 117)

Leptin

 Baseline

0.92 (0.87–0.98); p = 0.005

0.86 (0.78–0.95); p = 0.004

C3

 Baseline

0.13 (0.04–0.44); p = 0.001

0.15 (0.04–0.61); p = 0.008

TIMP-1

 Baseline

1.02 (1.01–1.03); p = 0.005

1.02 (1.01–1.04); p = 0.001

 Change from baseline to week 14

0.98 (0.97–1.00); p = 0.030

0.96 (0.94–0.98); p = 0.000

  1. Abbreviations: C3 Complement component 3, TIMP-1 Tissue inhibitor of metalloproteinase-1